^
Association details:
Biomarker:LAG3 overexpression
Cancer:Melanoma
Drug Class:PD1 inhibitor
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Soluble immune checkpoints and T-cell subsets in blood as biomarkers for resistance to immunotherapy in melanoma patients

Published date:
05/07/2021
Excerpt:
CONTRADICTING EVIDENCE:...resistance to antiPD1 treatment (n=48) was associated with high pre-treatment serum levels of sLAG3 (DCR: p=0.009; PFS: p=0.018; ROC cut-off > 148 pg/ml)…soluble immune checkpoints characterized checkpoint inhibitor-resistant melanoma.
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Transcriptomic and immunophenotypic profiles of melanoma tissue from patients (pts) treated with anti-PD-1 +/- ipilimumab to define mechanisms of response and resistance.

Published date:
05/16/2018
Excerpt:
141 melanoma biopsies from advanced melanoma pts treated with anti-PD-1 monotherapy (n= 54), or anti-PD1 + ipilimumab (n= 51) were classified as responders (CR/PR/SD > 6 mo) or non-responders (SD≤6 mo/PD) based on RECIST....Responders to monotherapy displayed increased expression of genes associated with a Type 1 interferon response, tissue-resident T-cells and drug targets (TIGIT, ADAR, ADORA2A, CD137, IDO1 and LAG3) (diff. p < 0.05).
DOI:
10.1200/JCO.2018.36.15_suppl.9518